Posted by Michael Wonder on 20 May 2017
Novartis receives positive CHMP opinion for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer
19 May 2017 - Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival over standard of care chemotherapy with maintenance, including in patients with brain metastases.
Novartis today announced the CHMP of the European EMA has recommended approval of expanding the use of Zykadia (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
If approved, Zykadia will provide a new treatment option for previously untreated and newly diagnosed patients with ALK-positive advanced NSCLC.
